Complete Revascularization after Pharmacoinvasive Strategy

Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI.  

Revascularización completa luego de estrategia fármaco invasiva

The COMPLETE showed that staged non-culprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in STEMI patients with multivessel coronary artery disease. This benefit was not clear for patients initially receiving antithrombotic medication not being able to access PCI right away. 

Following successful culprit lesion PCI, STEMI 4041 patients with multivessel disease were randomized to either routine non-culprit lesion PCI or culprit lesion only PCI. 

In a COMPLETE prespecified analysis, effect in 303 patients undergoing a pharmacoinvasive strategy was determined against 3738 patients undergoing primary PCI. Two primary end points were defined: on the one hand, cardiovascular death or new myocardial infarction and on the other hand, cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. 

The first primary end point was reduced with complete revascularization both in the patients undergoing a pharmacoinvasive strategy (2.1% vs 4.7%, HR 0.45, 95% CI, 0.21–0.97) and in patients undergoing primary PCI (2.7% vs 3.6%, HR 0.77, 95% CI, 0.62–0.95; interaction P=0.18). 


Read also: SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection.


The second primary end point was also reduced significantly with complete revascularization in patients undergoing an initial pharmacoinvasive strategy and in patients undergoing primary PCI.

Conclusion

Patients with multivessel disease with STEMI benefit from complete revascularization after treating the culprit lesion both with primary PCI and initial pharmacoinvasive strategy. 

Orignal Title: Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial.

Reference: Payam Dehghani et al. Circ Cardiovasc Interv. 2021 Aug;14(8):e010458. doi: 10.1161/CIRCINTERVENTIONS.120.010458.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...